Miruna Sasu, CEO of COTA, has been labeled as a disrupter in the industry. In this discussion, she highlights the challenges of investing in the life sciences industry. She also suggests how the investor mindset needs to change as well as offer solutions that benefit both investors and developers seeking investment. Host<a href="https://www.linkedin.com/in/lorielliskatz/">⁠⁠Lori Ellis⁠⁠</a>, Head of Insights, BioSpace Guests<a href="https://www.linkedin.com/in/miruna-sasu-7198a113/" target="_blank">Miruna Sasu</a>, President and CEO, COTA Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

A Conversation With Kevin Marks, CEO of Delphia

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.